Please assess the completion status of the following clinical trial:

Trial Title: A Study to Examine the Safety and Efficacy of Drospirenone and Ethinyl Estradiol (YAZ) Versus Placebo In HS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
INCLUSION CRITERIA~1. Female Subjects 14-45 years of age who have achieved spontaneous menarche.~2. Clinical diagnosis of hidradenitis suppurativa of stage II or greater on the Hurley scale.~3. Willing and able to understand and sign informed consent.~4. Able to complete study and comply with study procedures.~EXCLUSION CRITERIA~1. Change is use of oral or topical antibiotics in past 90 days.~2. Use of intralesional steroids within 30 days.~3. Use of isotretinoin in past six months.~4. Use of biologics such as Infliximab (Remicade®) or Etanercept (Enbrel®) within the past 3 months or 5 half lives (whichever is shorter).~5. History of renal insufficiency~6. History of hepatic dysfunction~7. History of adrenal Insufficiency~8. History of vascular or metabolic disease including existing or previous arterial thromboembolic diseases (myocardial infarction, stroke), existing or previous venous thromboembolic diseases (deep vein thrombosis, pulmonary embolism), and any condition which could increase the risk to suffer any of the above mentioned disorders~9. History of hypertension~10. History of Diabetes mellitus with vascular involvement~11. Migraine headaches with focal neurological symptoms~12. Major surgery with prolonged immobilization~13. Known or suspected carcinoma of the breast~14. History of Carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia~15. Undiagnosed abnormal genital bleeding~16. Cholestatic jaundice of pregnancy or jaundice with prior pill use~17. History of Liver tumor (benign or malignant) or active liver disease~18. Smokers~19. Regular intake of medications that may increase potassium levels such as NSAIDS, potassium sparing diuretics, potassium supplementation, ACE inhibitors, Angiotensin-II receptor antagonists, heparin and aldosterone antagonists.~20. Hypersensitivity to any component of the study drug~21. Clinically significant abnormal findings or conditions (other than acne), which might, in the opinion of the Principal Investigator, interfere with study evaluations or pose a risk to subject safety during the study.~22. Subjects who are known to be pregnant or planning a pregnancy.

- Gender: FEMALE
- Minimum Age: 14 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): drospirenone and ethinyl estradiol
- B (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).